Cas:1067914-81-1 1-benzyl-3,3-difluoropiperidine-4,4-diol manufacturer & supplier

Chemical Name:1-benzyl-3,3-difluoropiperidine-4,4-diol

CAS.NO:1067914-81-1

Synonyms:3,3-difluoro-1-(phenylmethyl)-4,4-piperidinediol;1-BENZYL-3,3-DIFLUORO-4,4-PIPERIDINEDIOL;C-8394

Molecular Formula:C₁₂H₁₅F₂NO₂

Molecular Weight:243.25000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:43.70000

Exact Mass:243.10700

LogP:1.14640

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3,3-difluoro-1-(phenylmethyl)-4,4-piperidinediol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,C-8394 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,3-difluoro-1-(phenylmethyl)-4,4-piperidinediol Use and application,1-BENZYL-3,3-DIFLUORO-4,4-PIPERIDINEDIOL technical grade,usp/ep/jp grade.

Related News: The on-body wear is similar to that of an insulin pump. Unlike insulin pump therapy, however, the investigational system is designed such that users enter only their body weight for the iLet to initialize therapy. 1-benzyl-3,3-difluoropiperidine-4,4-diol manufacturer In the process of fine chemical industry transfer, intermediates are a very important category, and they are also the main link for China to undertake transfers. 1-benzyl-3,3-difluoropiperidine-4,4-diol supplier ��We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,�� said Ed Damiano, President and CEO of Beta Bionics. ��We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.�� 1-benzyl-3,3-difluoropiperidine-4,4-diol vendor Darzalex has its own VRd combo trials, dubbed PERSEUS and CEPHEUS, which are testing a newly approved under-the-skin version of the J&J drug called Darzalex Faspro. The CEPHEUS trial appears to have just completed its primary analysis, according to a listing on ClinicalTrials.gov. 1-benzyl-3,3-difluoropiperidine-4,4-diol factory ��We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,�� said Ed Damiano, President and CEO of Beta Bionics. ��We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.��